The Chicken or the Egg? Genetic Testing Coverage

  • August 16, 2018
  • 1:00 PM – 2:00 PM ET
  • Online

Genomic medicine has the potential to revolutionize clinical practice. Genetic tests can assess disease risk, inform preventive measures, predict optimal therapeutic regimens, and more.

Early detection through genetic screening can reduce the financial impact on members and health systems by lowering downstream cost of care.

In order for members to widely benefit from advances in genomics, genetic tests must be incorporated into medical health plan design.

Attendees will learn: 

  • Gain a greater understanding about the genetics testing market
  • Understanding of CMS NCD decision regarding Next Gen Sequencing
  • Frameworks for evaluating genetic tests

Featured Speakers

Yuri Fesko, M.D, Medical Director of Oncology, Quest Diagnostics

As a leading oncologist, Dr. Fesko plays a key role in helping Quest advance the field of precision medicine and give new hope to people with cancer.

Prior to joining Quest in 2017, Dr. Fesko was Director of Medical Oncology at Duke Cancer Institute in Raleigh, North Carolina, where he was responsible for the oncology service line and development of inpatient oncology, multiple network sites and infusion centers. He was also responsible for strategies including the determination of appropriate clinical trials for population and resource utilization.

Dr. Fesko received his bachelor’s degree and medical degree from Case Western Reserve University School of Medicine. He is certified by the American Board of Internal Medicine in hematology and medical oncology.

Suzanne Belinson, Ph.D., M.P.H, Executive Director of Clinical Markets, Blue Cross and Blue Shield Association.

As the Executive Director, Dr. Belinson leads the sales and market development for products and services developed within the Office of Clinical Affairs. In addition, as part of the leadership team in the Office of Clinical Affairs she focuses on the development of emerging programs and services that enhance value and brand leadership for the independent BCBS Plans.

Before joining BCBSA, Dr. Belinson served as a NIH Clinical Cancer Fellow at Northwestern University where her work focused on community based interventions. Dr. Belinson developed and tested community based models for cervical cancer screening with both domestic and international applications. Dr. Belinson continues to serve as adjunct faculty at Northwestern University.

Dr. Belinson received her bachelor’s degree from Cleveland State University, and a PhD in Epidemiology from the University of North Carolina at Chapel Hill. She also holds a Masters in Public Health from the University of Pittsburgh.


Patrick James, MD, Chief Clinical Officer, Health Plans and Policy, Quest Diagnostics.

Dr. James earned his medical degree with honors from St. Louis University. He completed his internship and residency training in anatomic and clinical pathology with board certification at the National Naval Medical Center and post-graduate training in cytopathology with board certification at Johns Hopkins Hospital. Dr. James has served in leadership positions at Quest Diagnostics and other leading healthcare organizations, as well as the U.S. Navy.